With the rising demand for weight-loss medications, compounding pharmacies have been making headlines lately. On October 30, the FDA announced that all doses of Novo Nordisk’s Ozempic and Wegovy ...

Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...

Some health care providers say they’re starting to feel more comfortable prescribing compounded versions of the blockbuster weight loss drugs Wegovy and Zepbound, even as others have lingering ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients. Copycat medications, produced through a ...